Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tombach, B.
Right arrow Articles by Heindel, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tombach, B.
Right arrow Articles by Heindel, W.
(Radiology. 2001;218:651-657.)
© RSNA, 2001

Contrast Media

Renal Tolerance of a Neutral Gadolinium Chelate (gadobutrol) in Patients with Chronic Renal Failure: Results of a Randomized Study1

Bernd Tombach, MD, Christoph Bremer, MD, Peter Reimer, MD, Klaus Kisters, MD, Roland M. Schaefer, MD, Viviane Geens, MD and Walter Heindel, MD

1 From the Departments of Clinical Radiology (B.T., C.B., P.R., W.H.) and Internal Medicine (K.K., R.M.S.), Westfalian Wilhelms University of Münster, Albert-Schweitzer Str 33, Münster D-48129, Germany; and Schering, Berlin, Germany (V.G.). From the 1998 RSNA scientific assembly. Received November 10, 1999; revision requested January 5, 2000; revision received July 31; accepted August 30. Supported in part by Schering. Address correspondence to B.T. (e-mail: tombach@uni-muenster.de).

PURPOSE: To assess the renal tolerance of 1.0 mol/L gadobutrol as an electrically neutral contrast agent at magnetic resonance (MR) imaging in patients with impaired renal function.

MATERIALS AND METHODS: Twenty-one patients with impaired renal function were enrolled in this prospective randomized study and classified into two subgroups according to their creatinine clearance: group 1 (n = 12), less than 80 mL/min (<1.33 mL/sec) and greater than 30 mL/min (>0.50 mL/sec); group 2 (n = 9), less than 30 mL/min (<0.50 mL/sec) and not requiring dialysis. Gadobutrol (1.0 mol/L) was injected intravenously at randomly assigned doses of either 0.1 or 0.3 mmol per kilogram of body weight. Changes in vital signs, clinical chemistry, and urinalysis results, including creatinine clearance, were monitored before, at 6 hours, and then every 24 hours until 72 hours (group 1) or 120 hours (group 2) after intravenous injection of gadobutrol. Hematologic results were checked every other day.

RESULTS: No serious adverse event occurred, and no clinically relevant changes in vital signs, hematologic results, clinical chemistry, or urinalysis results were detected in the observation period. Markers for glomerular filtration (creatinine, cystatin C, ß2-microglobulin, creatinine clearance) and tubular function (N-acetyl-ß-D-glucosaminidase, {alpha}1-microglobulin) were unaffected by gadobutrol in both groups.

CONCLUSION: Gadobutrol did not affect renal function and, therefore, proved to be a safe MR contrast agent in patients with impaired renal function. Even in patients with marginal excretory function (creatinine clearance, <30 mL/min [<0.50 mL/sec]), prehydration or treatment with diuretics or hemodialysis are not required after the administration of gadobutrol.

Index terms: Gadolinium • Kidney, failure, 81.699 • Kidney, MR, 81.12143 • Kidney neoplasms, MR, 81.32, 81.12143 • Magnetic resonance (MR), contrast media, 81.12143




This article has been cited by other articles:


Home page
 RadiologyHome page
R. Habibi, M. S. Krishnam, D. G. Lohan, F. Barkhordarian, M. Jalili, R. S. Saleh, S. G. Ruehm, and J. P. Finn
High-Spatial-Resolution Lower Extremity MR Angiography at 3.0 T: Contrast Agent Dose Comparison Study
Radiology, August 1, 2008; 248(2): 680 - 692.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
M Fenchel, A Franow, P Martirosian, M Engels, U Kramer, N I Stauder, U Helber, H Vogler, C D Claussen, and S Miller
1 M Gd-chelate (gadobutrol) for multislice first-pass magnetic resonance myocardial perfusion imaging
Br. J. Radiol., November 1, 2007; 80(959): 884 - 892.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
A. Boss, P. Martirosian, M. Gehrmann, F. Artunc, T. Risler, N. Oesingmann, C. D. Claussen, F. Schick, K. Kuper, and H.-P. Schlemmer
Quantitative Assessment of Glomerular Filtration Rate with MR Gadolinium Slope Clearance Measurements: A Phase I Trial
Radiology, March 1, 2007; 242(3): 783 - 790.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
G. Andreisek, T. Pfammatter, K. Goepfert, D. Nanz, P. Hervo, R. Koppensteiner, and D. Weishaupt
Peripheral Arteries in Diabetic Patients: Standard Bolus-Chase and Time-resolved MR Angiography
Radiology, December 19, 2006; (2006) 2422051111.
[Abstract] [Full Text]

Home page
 RadiologyHome page
M. Remy-Jardin, J. Bahepar, J.-J. Lafitte, P. Dequiedt, O. Ertzbischoff, J. Bruzzi, V. Delannoy-Deken, A. Duhamel, and J. Remy
Multi-Detector Row CT Angiography of Pulmonary Circulation with Gadolinium-based Contrast Agents: Prospective Evaluation in 60 Patients
Radiology, March 1, 2006; 238(3): 1022 - 1035.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. Prokop, G. Schneider, A. Vanzulli, M. Goyen, S. G. Ruehm, P. Douek, M. Dapra, G. Pirovano, M. A. Kirchin, and A. Spinazzi
Contrast-enhanced MR Angiography of the Renal Arteries: Blinded Multicenter Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine
Radiology, February 1, 2005; 234(2): 399 - 408.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. M. Erley, B. D. Bader, E. D. Berger, N. Tuncel, S. Winkler, G. Tepe, T. Risler, and S. Duda
Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients
Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2526 - 2531.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. J. Doorenbos, A. Ozyilmaz, and M. van Wijnen
Severe Pseudohypocalcemia after Gadolinium-Enhanced Magnetic Resonance Angiography
N. Engl. J. Med., August 21, 2003; 349(8): 817 - 818.
[Full Text] [PDF]

Home page
 RadiologyHome page
B. Tombach, T. Benner, P. Reimer, G. Schuierer, E.-M. Fallenberg, V. Geens, T. Wels, and A. G. Sorensen
Do Highly Concentrated Gadolinium Chelates Improve MR Brain Perfusion Imaging? Intraindividually Controlled Randomized Crossover Concentration Comparison Study of 0.5 versus 1.0 mol/L Gadobutrol
Radiology, March 1, 2003; 226(3): 880 - 888.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
S. S. Sonnad
Describing Data: Statistical and Graphical Methods
Radiology, December 1, 2002; 225(3): 622 - 628.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
D. J. Spinosa, J. A. Kaufmann, and G. D. Hartwell
Gadolinium Chelates in Angiography and Interventional Radiology: A Useful Alternative to Iodinated Contrast Media for Angiography
Radiology, May 1, 2002; 223(2): 319 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
B. Tombach, C. Bremer, P. Reimer, F. Matzkies, R. M. Schaefer, W. Ebert, V. Geens, J. Eisele, and W. Heindel
Using Highly Concentrated Gadobutrol as an MR Contrast Agent in Patients Also Requiring Hemodialysis: Safety and Dialysability
Am. J. Roentgenol., January 1, 2002; 178(1): 105 - 109.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2001 by the Radiological Society of North America.